Dexanabinol

Clinical trials

Dexanabinol has been studied in IV administration and oral dosing. e-Therapeutics is evaluating the compound in clinical trials for brain and solid cancers. Phase II studies are planned based on the results of the current trials.

A phase 1b study for hepatocellular carcinoma and pancreatic cancer was started in 2015.

Legal status

HU-211 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971, so the signatory countries to these international drug control treaties are not required by said treaties to control HU-211.

United States

HU-211 is not listed in the list of scheduled controlled substances in the USA. It is therefore not scheduled at the federal level in the United States, but it is possible that HU-211 could legally be considered an analog of Delta-8-THC (one of the THC isomers which is in Schedule I under the designation of "Tetrahydrocannabinols"), and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.

HU-211 is a Schedule I controlled substance in Alabama.

HU-211 is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.

Effective January 1, 2016, HU-211 is a regulated drug in Vermont designated as a "Hallucinogenic Drug."

References

References

1. "e-therapeutics Clinical Development Pipeline".
2. PubChem. "Dexanabinol".
3. (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design.
4. (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America.
5. (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research.
6. (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs.
7. (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics.
8. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". The Lancet. Neurology.
9. University of California, San Diego "[http://www.laboratoryequipment.com/news/2012/09/synthetic-cannabinoid-may-be-used-brain-cancer-treatment Synthetic Cannabinoid May Be Used as Brain Cancer Treatment]". (28 September 2012) ''Laboratory Equipment''. Retrieved 28 September 2012.
10. (January 26, 2015). "A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours". NIH.
11. (18 December 2014). "e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies".
12. "Clinical Development Pipeline".
13. "A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours - Full Text View - ClinicalTrials.gov".
14. "UN International Drug Control Conventions".
15. "§1308.11 Schedule I.".
16. [https://www.erowid.org/psychoactives/law/analog/analog_info1.shtml Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary]
17. (March 2014). "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd.".
18. [http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]
19. [http://www.healthvermont.gov/sites/default/files/documents/2017/01/REG_regulated-drugs.pdf Vermont DOH - Regulated Drug Rule 2016 .PDF]